Clinical Trial Update: A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment [Phase 3]

View source ↗

Summary

ClinicalTrials.gov entry for a Phase 3 study of BL-M05D1 vs investigator's choice in CLDN18.2-positive advanced gastric cancer or gastroesophageal junction aden…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• BL-M05D1

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Status: NOT_YET_RECRUITING